Skip to main content

Oncogenic pathway signatures in human cancers as a guide to targeted therapies.

Publication ,  Journal Article
Bild, AH; Yao, G; Chang, JT; Wang, Q; Potti, A; Chasse, D; Joshi, M-B; Harpole, D; Lancaster, JM; Berchuck, A; Olson, JA; Marks, JR; West, M ...
Published in: Nature
January 19, 2006

The development of an oncogenic state is a complex process involving the accumulation of multiple independent mutations that lead to deregulation of cell signalling pathways central to the control of cell growth and cell fate. The ability to define cancer subtypes, recurrence of disease and response to specific therapies using DNA microarray-based gene expression signatures has been demonstrated in multiple studies. Various studies have also demonstrated the potential for using gene expression profiles for the analysis of oncogenic pathways. Here we show that gene expression signatures can be identified that reflect the activation status of several oncogenic pathways. When evaluated in several large collections of human cancers, these gene expression signatures identify patterns of pathway deregulation in tumours and clinically relevant associations with disease outcomes. Combining signature-based predictions across several pathways identifies coordinated patterns of pathway deregulation that distinguish between specific cancers and tumour subtypes. Clustering tumours based on pathway signatures further defines prognosis in respective patient subsets, demonstrating that patterns of oncogenic pathway deregulation underlie the development of the oncogenic phenotype and reflect the biology and outcome of specific cancers. Predictions of pathway deregulation in cancer cell lines are also shown to predict the sensitivity to therapeutic agents that target components of the pathway. Linking pathway deregulation with sensitivity to therapeutics that target components of the pathway provides an opportunity to make use of these oncogenic pathway signatures to guide the use of targeted therapeutics.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Nature

DOI

EISSN

1476-4687

Publication Date

January 19, 2006

Volume

439

Issue

7074

Start / End Page

353 / 357

Location

England

Related Subject Headings

  • Survival Analysis
  • Signal Transduction
  • Reproducibility of Results
  • Pharmacogenetics
  • Ovarian Neoplasms
  • Oncogenes
  • Oligonucleotide Array Sequence Analysis
  • Neoplasms
  • Mice
  • Lung Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., … Nevins, J. R. (2006). Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature, 439(7074), 353–357. https://doi.org/10.1038/nature04296
Bild, Andrea H., Guang Yao, Jeffrey T. Chang, Quanli Wang, Anil Potti, Dawn Chasse, Mary-Beth Joshi, et al. “Oncogenic pathway signatures in human cancers as a guide to targeted therapies.Nature 439, no. 7074 (January 19, 2006): 353–57. https://doi.org/10.1038/nature04296.
Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006 Jan 19;439(7074):353–7.
Bild, Andrea H., et al. “Oncogenic pathway signatures in human cancers as a guide to targeted therapies.Nature, vol. 439, no. 7074, Jan. 2006, pp. 353–57. Pubmed, doi:10.1038/nature04296.
Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi M-B, Harpole D, Lancaster JM, Berchuck A, Olson JA, Marks JR, Dressman HK, West M, Nevins JR. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006 Jan 19;439(7074):353–357.

Published In

Nature

DOI

EISSN

1476-4687

Publication Date

January 19, 2006

Volume

439

Issue

7074

Start / End Page

353 / 357

Location

England

Related Subject Headings

  • Survival Analysis
  • Signal Transduction
  • Reproducibility of Results
  • Pharmacogenetics
  • Ovarian Neoplasms
  • Oncogenes
  • Oligonucleotide Array Sequence Analysis
  • Neoplasms
  • Mice
  • Lung Neoplasms